Views & Analysis Is UK biotech facing a Brexit brain drain? Restrictions on EU migration would hurt UK biotech.
Views & Analysis Coming of age: Alnylam and the RNAi revolution Alynylam has a crucial two years ahead of it, but it and RNAi could be about to come of age.
News Circassia shares plummet following cat allergy therapy failu... Company said the failure could have implications for its other products under development
News Roche's IgAN hopeful sefaxersen passes phase 3 test Roche has staked a claim to the increasingly crowded IgA nephropathy (IgAN) category with phase 3 data for Ionis-partnered sefaxersen.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
